Sana Biotechnology

### Executive Summary Sana Biotechnology raised $540.2M in a Regulation D private placement, with first sale on 2025-10-12, indicating strong institutional demand for synthetic biology and intracellular mRNA delivery platforms. The involvement of Lockheed Martin Ventures and Bessemer Venture Partners as related persons suggests strategic and venture capital confidence in the company's technology. This is a Form D initial notice, not an amendment, implying the capital raise is fresh and potentially still open. ### Investor Edge Watch for a subsequent Form D/A (amendment) that could reveal additional investors or an increased target amount, signaling further momentum. Also, track any public announcements from Lockheed Martin or Bessemer regarding follow-on investments or partnerships. ### Sector capital positioning This $540.2M raise signals a major capital flow into synthetic biology and mRNA delivery, a sector that continues to attract large private placements despite broader market volatility. The size and timing suggest investors are betting on long-term platform value rather than near-term public exits. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data. However, the presence of Lockheed Martin Ventures hints at potential defense or aerospace applications for mRNA delivery, which could be a convergence point to monitor. ### Key Takeaways - Sana Biotechnology raised $540.2M in a private placement, one of the largest synthetic biology raises in recent years. - Lockheed Martin Ventures and Bessemer Venture Partners are listed as related persons, indicating strategic and VC backing. - The Form D is an initial notice, not an amendment, suggesting the raise is new and may expand. ### Risk Indicators & Flags No red flags in the filing itself (Form D, not D/A). However, the massive $540.2M raise for a private company with no public ticker could indicate high burn rate or pre-IPO positioning. Regulatory risks in synthetic biology and mRNA delivery are inherent but not flagged in this filing. ### Verification & References Verify filing details via SEC EDGAR using accession number 0001702600-24-20223. Confirm first sale date (2025-10-12) and related persons (Lockheed Martin Ventures, Bessemer Venture Partners) on the SEC filing page. No public ticker exists; this is a private company.